Retaspimycin (Hydrochloride)
Retaspimycin Hydrochloride is a potent inhibitor of Hsp90 with EC50s of 119 nM for both Hsp90 and Grp9.
Product Specifications
CAS Number
857402-63-2
Product Name Alternative
IPI-504
UNSPSC
12352005
Target
HSP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Retaspimycin-Hydrochloride.html
Purity
96.16
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=C2O)/C(C)=C/C=C\[C@H](OC)[C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC2=C(C(O)=C1)NCC=C)C)OC)O)C)OC(N)=O.Cl
Molecular Formula
C31H46ClN3O8
Molecular Weight
624.17
References & Citations
[1]Patterson J, et al. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol. 2008 May;61 (6) :923-32.|[2]Scaltriti M, et al. Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Mol Cancer Ther. 2011 May;10 (5) :817-24.|[3]Sydor JR, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A. 2006 Nov 14;103 (46) :17408-13. Epub 2006 Nov 7.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
HSP90
Citation 01
FASEB J. 2023 Mar;37 (3) :e22832.|J Cell Biochem. 2025 Apr;126 (4) :e70031.|Theranostics. 2019 Aug 12;9 (20) :5769-5783.|Transl Oncol. 2019 Apr 3;12 (6) :801-809.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
